Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Huang, Hu ^a   Shen, Jikui ^a   Vinores, Stanley A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; CHEMOKINE RECEPTOR CXCR4; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MANNITOL; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY MF 1; NEUTRALIZING ANTIBODY; PLACENTAL GROWTH FACTOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN B; ANGIOGENIC FACTOR; LECTIN; LIGAND; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; GENE EXPRESSION REGULATION; MICROGLIA; MONOTHERAPY; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BLOCKING; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; SUBRETINAL NEOVASCULARIZATION; UPREGULATION; ANIMAL; BLOOD VESSEL; DRUG ANTAGONISM; EYE; INFLAMMATION; ISCHEMIA; METABOLISM; PATHOLOGY; RETINA; RETINA DISEASE; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BLOOD VESSELS; CHOROIDAL NEOVASCULARIZATION; EYE; INFLAMMATION; ISCHEMIA; LECTINS; LIGANDS; MICE; MICROGLIA; RETINA; RETINAL DISEASES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79959515272     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021411     Document Type: Article

References (68)

1. Adamis AP, Miller JW, Bernal M-T, D'Amico DJ, Folkman J, et al. (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Amer J Ophthalmol 118: 445-450.
2. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl J Med 331: 1480-1487.
3. Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, et al. (1994) Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112: 1476-1482.
4. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, et al. (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 72: 638-645.
5. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, et al. (1994) Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145: 574-584.
6. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH, (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92: 905-909.
7. Shweiki D, Itin A, Soffer D, Keshet E, (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845.
8. Dor Y, Keshet E, (2000) Ischemia-driven angiogenesis. Trends Cardiovasc Med 7: 289-294.
9. Semenza GL, (2000) Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol 59: 47-53.
10. Semenza GL, Agani F, Iyer N, Jiang BH, Leung S, et al. (1998) Hypoxia-inducible factor 1: from molecular biology to cardiopulmonary physiology. Chest 114: 40S-45S.
11. Vinores SA, Xiao W-H, Aslam S, Shen J, Oshima Y, et al. (2006) Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol 206: 749-758.
12. Wang J, Xu X, Elliott MH, Zhu M, Le YZ, (2010) Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes 59: 2297-2305.
13. Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, et al. (1997) Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151: 281-291.
14. Vinores SA, Seo MS, Okamoto N, Ash JD, Wawrousek EF, et al. (2002) Experimental models of growth factor-mediated angiogenesis and blood-retinal barrier breakdown. General Pharmacology: The Vascular System 35: 233-239.
15. Folkman J, (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
16. Ferrara N, (2010) Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21: 21-26.
17. Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M, (2007) Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA 104: 967-972.
18. Carmeliet P, (2005) Angiogenesis in life, disease and medicine. Nature 438: 932-936.
19. Kumar A, Hou X, Lee C, Li Y, Maminishkis A, et al. (2010) Platelet-derived growth factor-DD targeting arrests pathological angiogenesis by modulating glycogen synthase kinase-3beta phosphorylation. J Biol Chem 285: 15500-15510.
20. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, et al. (2003) Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 3186-3193.
21. Vinores SA, (2007) Anti-VEGF therapy for ocular vascular diseases. In: Angiogenesis: Basic Science and Clinical Applications, Maragoudakis ME & Papadimitriou E editors. Transworld Research Network, Kerala, India, Chapter 28: 467-482.
22. Witmer AN, Blaauwgeers HG, Weich HA, Alitalo K, Vrensen GF, et al. (2002) Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci 43: 849-857.
23. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, et al. (1998) A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273: 31273-31282.
24. Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, et al. (1999) A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18: 363-374.
25. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M, (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95: 9349-9354.
26. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, et al. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583.
27. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, et al. (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8: 831-840.
28. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, et al. (2010) Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141: 178-190.
29. Rockwell P, Goldstein N, (1995) Role of protein tyrosine kinase receptors in cancer: Possibilities for therapeutic intervention. Mol Cell Diff 3: 315-335.
30. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, et al. (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209-5218.
31. Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MA, Targeting autocrine paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004; 104: 2893-2902.
32. Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H, Mangalampalli VR, Ludwig DL, Tonra JR, Hicklin DJ, Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 2006; 12: 6573-6584.
33. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, Rafii S, Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001 98: 10857-10862.
34. Huang H, Frank MB, Dozmorov I, Cao W, Cadwell C, et al. (2005) Identification of mouse retinal genes differentially regulated by dim and bright cyclic light rearing. Exp Eye Res 80: 727-739.
35. Huang H, Wahlin KJ, McNally M, Irving ND, Adler R, (2008) Developmental regulation of muscleblind-like (MBNL) gene expression in the chicken embryo retina. Dev Dyn 237: 286-296.
36. Robinson GS, Ju M, Shih SC, Xu X, McMahon G, et al. (2001) Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. FASEB J 15: 1215-1217.
37. Zhong XF, Huang H, Shen JK, Zentilin L, Giacca M, et al. (2011) Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation. Mol Vis 17: 492-507.
38. Yoshida T, Zhang H, Iwase T, Shen J, Semenza GL, et al. (2010) Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J 24: 1759-1767.
39. Tobe T, Okamoto N, Vinores M, Derevjanik NL, Vinores SA, et al. (1998) Evolution of neovascularization in mice with overexpression of VEGF in photoreceptors. Invest Ophthalmol Vis Sci 39: 180-188.
40. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, et al. (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35: 101-111.
41. Connor KM, Krah NM, Dennison RJ, Ademan CM, Chen J, et al. (2009) Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc 4: 1565-1573.
42. Huang H, Vasilakis P, Zhong X, Shen JK, Geronatsiou K, et al. (2010) Parstatin suppresses ocular neovascularization and inflammation. Invest Ophthalmol Vis Sci 51: 5825-5832.
43. Derevjanik NL, Vinores SA, Xiao WH, Mori K, Turon T, et al. (2002) Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci 43: 2462-2467.
44. Verbeke G, Molenberghs G, (2000) Linear Mixed Models for Longitudinal Data. New York Springer-Verlag, Inc.
45. Shen J, Xie B, Dong A, Swaim M, Hackett SF, Campochiaro PA, (2007) In vivo immunostaining demonstrates macrophages associated with growing and regressing vessels. Invest Ophthalmol Vis Sci 48: 4335-4341.
46. Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri C, et al. (2000) Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol 184: 275-284.
47. Chang KH, Chan-Ling T, McFarland EL, Afzal A, Pan H, et al. (2007) IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Nat'l Acad Sci USA 104: 10595-10600.
48. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LE, (2009) Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 50: 1329-1335.
49. Ma W, Zhao L, Fontainhas AM, Fariss RN, Wong WT, (2009) Microglia in the mouse retina alter the structure and function of retinal pigmented epithelial cells: a potential cellular interaction relevant to AMD. PLoS One 20; 4: e7945.
50. Semkova I, Muether PS, Kuebbeler M, Meyer KL, Kociok N, et al. (2010) Recruitment of blood-derived inflammatory cells mediated via Tumor necrosis factor (TNF)-{alpha} receptor 1b exacerbates CNV. Invest Ophthalmol Vis Sci. In press.
51. Colton CA, Abel C, Patchett J, Keri J, Yao J, (1992) Lectin staining of cultured CNS microglia. J Histochem Cytochem 40: 505-512.
52. Roque RS, Caldwell RB, (1993) Isolation and culture of retinal microglia. Curr Eye Res 12: 285-290.
53. Ambati J, Anand A, Fernandez S, Sakurai E, Lynn BC, et al. (2003) An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med 9: 1390-1397.
54. Sengupta N, Afzal A, Caballero S, Chang KH, Shaw LC, Pang JJ, et al. (2010) Paracrine modulation of CXCR4 by IGF-1 and VEGF: implications for choroidal neovascularization. Invest Ophthalmol Vis Sci 51: 2697-2704.
55. Luhmann UF, Robbie S, Munro PM, Barker SE, Duran Y, et al. (2009) The drusenlike phenotype in aging Ccl2-knockout mice is caused by an accelerated accumulation of swollen autofluorescent subretinal macrophages. Invest Ophthalmol Vis Sci 50: 5934-5943.
56. Caicedo A, Espinosa-Heidmann DG, Piña Y, Hernandez EP, Cousins SW, (2005) Blood-derived macrophages infiltrate the retina and activate Muller glial cells under experimental choroidal neovascularization. Exp Eye Res 81: 38-47.
57. Guerin E, Sheridan C, Assheton D, Kent D, Wong D, et al. (2008) SDF1-alpha is associated with VEGFR-2 in human choroidal neovascularisation. Microvasc Res 75: 302-307.
58. Maiti D, Xu Z, Duh EJ, (2008) Vascular endothelial growth factor induces MEF2C and MEF2-dependent activity in endothelial cells. Invest Ophthalmol Vis Sci 49: 3640-3648.
59. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, et al. (2010) A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 9: 145-156.
60. Fu Y, Ponce ML, Thill M, Yuan P, Wang NS, et al. (2007) Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest Ophthalmol Vis Sci 48: 5184-5190.
61. Chappelow AV, Kaiser PK, (2008) Neovascular age-related macular degeneration: potential therapies. Drugs 68: 1029-1036.
62. Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M, (2007) Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci U S A 104: 967-972.
63. Dixon, JA, Oliver, SC, Olson, JL, Mandava, N, (2009) VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 18: 1573-1580.
64. Schlingemann, RO, Witmer, AN, (2009) Treatment of retinal diseases with VEGF antagonists. Prog Brain Res 175: 253-267.
65. Tuñón J, Ruiz-Moreno JM, Martín-Ventura JL, Blanco-Colio LM, Lorenzo O, et al. (2009) Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmo l 54: 339-348.
66. Sainson RC, Harris AL, (2008) Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis 11: 41-51.
67. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613.
68. Chen L, Yang P, Kijlstra A, (2002) Distribution, markers, and functions of retinal microglia. Ocul Immunol Inflamm 10: 27-39.